Eduardo R Fregnani1, Danyel E da Cruz Perez2, Oslei Paes de Almeida3, Felipe Paiva Fonseca3, Fernando A Soares4, Gilberto Castro-Junior5, Fábio A Alves6. 1. Department of Oral Medicine, Sírio-Libanês Hospital, São Paulo, Brazil. 2. Oral Pathology, Dental School, Federal University of Pernambuco, Recife, Brazil. 3. Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil. 4. Department of Pathology, A C Camargo Cancer Center, São Paulo, Brazil. 5. Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. 6. Department of Oral Medicine, A C Camargo Cancer Center, São Paulo, Brazil.
Abstract
AIMS: The aim of this study was to investigate whether the expression of BRAF-V600E determines an aggressive clinical and molecular presentation of ameloblastoma. METHODS AND RESULTS: Ninety-three cases of solid ameloblastomas were arranged in a 1.0-mm tissue microarray (TMA) block. Immunohistochemistry against a large panel of cytokeratins (CK), epidermal growth factor receptor (EGFR), parathyroid hormone-related peptide (PTHrP), syndecan-1, Ki67, p53 and BRAF-V600E were performed. Clinicopathological parameters, including sex, age, tumour size, tumour duration, tumour location, treatment, recurrences, radiographic pattern, vestibular/lingual and basal cortical plates disruption and follow-up data, were obtained from patients' medical records. Immunoexpression of BRAF-V600E was investigated in 73 cases that remained available in TMA sections. Our results indicated that 46.6% (34 cases) demonstrated cytoplasm positivity (six weak and 28 strong positivity). BRAF-V600E expression was associated significantly with the expression of CK8 (P = 0.00077), CK16 (P = 0.05), PTHrP (P = 0.0082) and p53 (P = 0.0087). Additionally, a significant association was seen with the presence of recurrences (P = 0.0008), multilocular radiographic appearance (P = 0.044) and disruption of basal bone cortical (P = 0.05). Univariate analysis showed that BRAF-positive cases (P = 0.001), EGFR-negative/weak positive cases (P = 0.03) and multilocular tumours (P = 0.04) had a significantly lower disease-free survival rate, but these parameters were not considered independent prognostic factors in the multivariate analysis (P > 0.05). CONCLUSIONS: Our findings suggest an association of BRAF-V600E with parameters of a more aggressive behaviour of ameloblastoma, supporting the future use of BRAF inhibitors for targeted therapy of this neoplasm.
AIMS: The aim of this study was to investigate whether the expression of BRAF-V600E determines an aggressive clinical and molecular presentation of ameloblastoma. METHODS AND RESULTS: Ninety-three cases of solid ameloblastomas were arranged in a 1.0-mm tissue microarray (TMA) block. Immunohistochemistry against a large panel of cytokeratins (CK), epidermal growth factor receptor (EGFR), parathyroid hormone-related peptide (PTHrP), syndecan-1, Ki67, p53 and BRAF-V600E were performed. Clinicopathological parameters, including sex, age, tumour size, tumour duration, tumour location, treatment, recurrences, radiographic pattern, vestibular/lingual and basal cortical plates disruption and follow-up data, were obtained from patients' medical records. Immunoexpression of BRAF-V600E was investigated in 73 cases that remained available in TMA sections. Our results indicated that 46.6% (34 cases) demonstrated cytoplasm positivity (six weak and 28 strong positivity). BRAF-V600E expression was associated significantly with the expression of CK8 (P = 0.00077), CK16 (P = 0.05), PTHrP (P = 0.0082) and p53 (P = 0.0087). Additionally, a significant association was seen with the presence of recurrences (P = 0.0008), multilocular radiographic appearance (P = 0.044) and disruption of basal bone cortical (P = 0.05). Univariate analysis showed that BRAF-positive cases (P = 0.001), EGFR-negative/weak positive cases (P = 0.03) and multilocular tumours (P = 0.04) had a significantly lower disease-free survival rate, but these parameters were not considered independent prognostic factors in the multivariate analysis (P > 0.05). CONCLUSIONS: Our findings suggest an association of BRAF-V600E with parameters of a more aggressive behaviour of ameloblastoma, supporting the future use of BRAF inhibitors for targeted therapy of this neoplasm.
Authors: Alan Motta do Canto; Barbara Michaela Reis da Silva Marcelino; Juliana Lucena Schussel; Bruna F Wastner; Laurindo Moacir Sassi; Luciana Corrêa; Ronaldo Rodrigues de Freitas; Bengt Hasséus; Göran Kjeller; Celso Augusto Lemos Junior; Paulo Henrique Braz-Silva Journal: Clin Oral Investig Date: 2018-05-31 Impact factor: 3.573
Authors: Adepitan A Owosho; Adeola M Ladeji; Kehinde E Adebiyi; Mofoluwaso A Olajide; Ikechukwu S I Okoye; Temitope Kehinde; Ngozi N Nwizu; Kurt F Summersgill Journal: Eur Arch Otorhinolaryngol Date: 2020-11-24 Impact factor: 2.503
Authors: Gustavo S Fernandes; Daniel M Girardi; João Paulo G Bernardes; Felipe P Fonseca; Eduardo R Fregnani Journal: BMC Cancer Date: 2018-09-12 Impact factor: 4.430
Authors: Gleyson Kleber do Amaral-Silva; Thayná Melo de Lima Morais; Vivian Petersen Wagner; Manoela Domingues Martins; Eduardo Rodrigues Fregnani; Fernando Augusto Soares; André Caroli Rocha; Helder Rabelo Pontes; Alan Roger Santos-Silva; Pablo Agustin Vargas Journal: Front Oral Health Date: 2021-10-26